发明名称 CNS活性剤としてのベンズイミダゾール類
摘要 The present invention relates to compounds of general formula wherein R1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or halogen; X1 is N or CH; X2 is N or CH; with the proviso that only one of X1 or X2 is N; X3 is C(R) or N; and R is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy or SO2-lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.
申请公布号 JP5947465(B2) 申请公布日期 2016.07.06
申请号 JP20150531611 申请日期 2013.09.27
申请人 エフ.ホフマン−ラ ロシュ アーゲーF. HOFFMANN−LA ROCHE AKTIENGESELLSCHAFT 发明人 チェッカレッリ,シモーナ・エム;ヤーガジア,ラヴィ;ヤーコップ−ルートネ,ローラント;ヴィッヒマン,ユルゲン
分类号 C07D401/14;A61K31/4184;A61K31/4439;A61P25/00;A61P25/14;A61P25/16;A61P25/18;A61P25/22;A61P25/24;A61P25/28;A61P25/36;A61P27/16;C07D403/04 主分类号 C07D401/14
代理机构 代理人
主权项
地址